Belantamab Mafodotin

A triplet regimen extended OS compared with the current standard of care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.

CHICAGO — In this video, Adam Cohen, MD, discussed findings from the DREAMM-7 and DREAMM-8 trials presented at ASCO Annual Meeting.

CHICAGO — Henry Chi Hang Fung, MD, FACP, FRCPE, spoke with Healio about findings from DREAMM-7 and DREAMM-8— both presented at ASCO Annual Meeting.

CHICAGO — The addition of belantamab mafodotin to pomalidomide and dexamethasone improved outcomes compared with standard care for patients with relapsed or refractory multiple myeloma, according to data presented at ASCO Annual Meeting.

The combination of belantamab mafodotin, pomalidomide and dexamethasone extended PFS compared with standard care for patients with relapsed or refractory multiple myeloma, according to a topline data announcement.

A triplet therapy showed significant improvement in PFS compared with the current standard-care regimen among patients with relapsed or refractory multiple myeloma, according to data presented during an ASCO Plenary Series session.

Belantamab mafodotin improved PFS — when combined with bortezomib and ddexamethasone — as second-line treatment among certain patients with multiple myeloma, according to topline data from the agent’s manufacturer.

CHICAGO — Belantamab mafodotin monotherapy did not significantly extend PFS compared with the combination of pomalidomide and dexamethasone among adults with relapsed or refractory multiple myeloma, phase 3 study results showed.

BOSTON – Loriel J. Solodokin, PharmD, BCOP, talked about the “innovative research” presented at the poster sessions at Hematology/Oncology Pharmacy Association Annual Meeting in a video interview.

The Institute for Clinical and Economic Review has completed a draft scoping document for its planned assessment of chimeric antigen receptor T-cell therapies for the treatment of multiple myeloma.